KN060
Phase 2Small molecule
KN060 is one of 36 small molecule programs targeting Essential Hypertension. It is currently in Phase 2.
2
Indications
3
Total Trials
3
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
54 competitors in Essential Hypertension
#DrugCompanyPhaseTrials
1Zebeta
TevaApproved
Tekturna
Tibotec Pharmaceuticals, IrelandApproved
Bayer Aspirin
BayerApproved
Rifadin
SanofiApproved
Cialis
Eli LillyApproved
Aldactone
PfizerApproved
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cardura
VViatris Specialty LLC
Approved
Nizoral
WWim Janssens
Approved
Coreg
Akero TherapeuticsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Total Knee Arthroplasty1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KN060. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSuzhou Alphamab Co., Ltd.